Praziquantel efficacy, urinary and intestinal schistosomiasis reinfection – a systematic review

References

• WHO Schistosomiasis (Bilharzia) [Internet]. World Health Organization; 2022. [cited 2022 Feb 8]. Available from: https://www.who.int/health-topics/schistosomiasis#tab=tab_1
   Google Scholar
• Ross AGP, Chau TN, Inobaya MT, et al. A new global strategy for the elimination of schistosomiasis. Inter J Infect Dis. 2017;54:130–137.
   PubMed Web of Science ®Google Scholar
• Butterworth AE, Sturrock RF, Ouma JH, et al. Comparison of different chemotherapy strategies against Schistosoma mansoni in Machakos District, Kenya: effects on human infection and morbidity. Parasitology. 1991;103(3):339–355.
   PubMedGoogle Scholar
• Colley DG, Bustinduy AL, Secor WE, et al. Human schistosomiasis. Lancet. 2014;383(9936):2253–2264.
   PubMed Web of Science ®Google Scholar
• Maseko TS, Mkhonta NR, Masuku SK, et al. Schistosomiasis knowledge, attitude, practices, and associated factors among primary school children in the Siphofaneni area in the Lowveld of Swaziland. J Microbiol Immunol Infect. 2018;51(1):103–109.
   PubMedGoogle Scholar
• Abo-Madyan AA, Morsy TA, Motawea SM. Efficacy of Myrrh in the treatment of schistosomiasis (haematobium and mansoni) in Ezbet El-Bakly, Tamyia Center, El-Fayoum Governorate, Egypt. J Egypt Soc Parasitol. 2004;34(2):423–446.
   PubMedGoogle Scholar
• WHO Expert Committee. (1985). The control of schistosomiasis. Report of a WHO Expert Committee. Geneva, World Health Organization, ( WHO Technical Report Series, No.728):1–113.
   Google Scholar
• WHO Expert Committee. (1980). Epidemiology and control of schistosomiasis. Report of a WHO Expert Committee. Geneva, World Health Organization, ( WHO Technical Report Series, No. 643):5–62.
   Google Scholar
• World Health Organization. (2002). Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. World Health Organization, Geneva. WHO Technical Report Series No. 912:1–57.
   Google Scholar
• Caffrey CR. Schistosomiasis and its treatment. Future Med Chem Chemistry. 2015;7(6):675–676.
   PubMed Web of Science ®Google Scholar
• Vale N, Gouveia MJ, Rinaldi G, et al. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother. 2017;61(5). e02582-16. DOI:10.1128/AAC.02582-16.
   PubMed Web of Science ®Google Scholar
• Cioli D, Pica-Mattoccia L, Basso A, et al. Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol Parasitology. 2014;195(1):23–29.
   PubMed Web of Science ®Google Scholar
• Stelma FF, Kongs I, Polman S, et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg. 1995;53(2):167–170.
   PubMed Web of Science ®Google Scholar
• Ismail M, Bennet A, Bruce A, et al. Characterization of isolates of Schistosoma mansoni from egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg. 1996;55(2):214–218.
   PubMed Web of Science ®Google Scholar
• Alonso D, Munoz J, Gascon J, et al. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg. 2006;74(2):342–344.
   PubMed Web of Science ®Google Scholar
• Herwaldt BL, Tao LF, van Pelt W, et al. Persistence of Schistosoma haematobium infection despite multiple courses of therapy with praziquantel. Clinl Infect Dis. 1995;20(2):309–315.
   PubMed Web of Science ®Google Scholar
• Dawaki S, Al-Mekhlafi HM, Ithoi I, et al. Prevalence and risk factors of schistosomiasis among Hausa communities in Kano State, Nigeria. Rev Inst Med Trop São Paulo. 2016;58(0). DOI:https://doi.org/10.1590/S1678-9946201658054
   PubMedGoogle Scholar
• Kabuyaya M, Chimbari MJ, Manyangadze T, et al. Schistosomiasis risk factors based on the infection status among school-going children in the Ndumo area, uMkhanyakude district, South Africa. S Afr J Infect Dis. 2017a;32(2):67–72.
   Web of Science ®Google Scholar
• Adenowo AF, Oyinloye BE, Ogunyinka BI, et al. Impact of human schistosomiasis in sub-Saharan Africa. Braz J Infect Dis. 2015;19(2):196–205.
   PubMed Web of Science ®Google Scholar
• Mbanefo EC, Huy NT, Wadagni AA, et al. Host determinants of reinfection with schistosomes in humans: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2014;8(9):e3164.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected tropical diseases 2015. Vol. 3. Geneva. World Health Organization; 2015.
   Google Scholar
• Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659–667.
   PubMed Web of Science ®Google Scholar
• Zacharia A, Mushi V, Makene T. A systematic review and meta-analysis on the rate of human schistosomiasis reinfection. PLoS One. 2020;15(12):e0243224.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269. DOI:10.7326/0003-4819-151-4-200908180-00135
   PubMed Web of Science ®Google Scholar
• Montresor A. Cure rate is not a valid indicator for assessing drug efficacy and impact of preventive chemotherapy interventions against schistosomiasis and soil-transmitted helminthiases. Trans R Soc Trop Med Hyg. 2011;105(7):361–363.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Assessing the efficacy of anthelminthic drugs against schistosomiasis and soil-transmitted helminthiases. 2013 [cited 2022 Feb 16]. Available from: https://apps.who.int/iris/handle/10665/79019
   Google Scholar
• Hoy D, Brooks P, Woolf A et al, Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934–939. DOI:10.1016/j.clinepi.2011.11.014
   PubMed Web of Science ®Google Scholar
• Coulibaly JT, N’Gbesso YK, Knopp S, et al. Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. PLoS Negl Trop Dis. 2012;6(12):e1917.
   PubMed Web of Science ®Google Scholar
• Garba A, Lamine MS, Barkiré N, et al. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop. 2013;128(2):334–344.
   PubMed Web of Science ®Google Scholar
• Guidi A, Andolina C, Makame Ame S, et al. Praziquantel efficacy and long‐term appraisal of schistosomiasis control in Pemba Island. Trop Med Int Health. 2010;15(5):614–618.
   PubMed Web of Science ®Google Scholar
• Jin Y, Lee YH, Cha S, et al. Transmission dynamics of Schistosoma haematobium among school-aged children: a cohort study on prevalence, reinfection and incidence after mass drug administration in the white nile state of Sudan. Int J Environ Res Public Health. 2021;18(21):11537.
   PubMed Web of Science ®Google Scholar
• Kabuyaya M, Chimbari MJ, Mukaratirwa S. Comparison of praziquantel efficacy at 40 mg/kg and 60 mg/kg in treating Schistosoma haematobium infection among schoolchildren in the Ingwavuma area, KwaZulu-Natal, South Africa. S Afr Med J. 2020;110(7):657–660.
   PubMed Web of Science ®Google Scholar
• Kabuyaya M, Chimbari MJ, Manyangadze T, et al. Efficacy of praziquantel on Schistosoma haematobium and re-infection rates among school-going children in the Ndumo area of uMkhanyakude district, KwaZulu-Natal, South Africa. Infect Dis Poverty. 2017b;6(1):1–9.
   PubMedGoogle Scholar
• Senghor B, Diaw OT, Doucoure S, et al. Efficacy of praziquantel against urinary schistosomiasis and reinfection in Senegalese school children where there is a single well-defined transmission period. Parasit Vectors. 2015;8(1):1–11.
   PubMed Web of Science ®Google Scholar
• Stete K, Krauth SJ, Coulibaly JT, et al. Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children. Parasit Vectors. 2012;5(1):1–10.
   PubMedGoogle Scholar
• Tchuenté LAT, Shaw DJ, Polla L, et al. Efficacy of praziquantel against Schistosoma haematobium infection in children. Am J Trop Med Hyg. 2004;71(6):778–782.
   PubMed Web of Science ®Google Scholar
• Bajiro M, Dana D, Ayana M, et al. Prevalence of Schistosoma mansoni infection and the therapeutic efficacy of praziquantel among school children in Manna District, Jimma Zone, southwest Ethiopia. Parasit Vectors. 2016;9(1):1–6.
   PubMedGoogle Scholar
• Dejenie T, Asmelash T, Abdelkadir M. Efficacy of praziquantel in treating Schistosoma mansoni infected school children in Tumuga and Waja, north Ethiopia. Momona Momona Ethiop J Sci. 2010;2(2):3–11.
   Google Scholar
• Degu G, Mengistu G, Jones J. Praziquantel efficacy against Schistosomiasis mansoni in schoolchildren in north-west Ethiopia. Trans R Soc Trop Med Hyg. 2002;96(4):444–445.
   PubMed Web of Science ®Google Scholar
• Erko B, Degarege A, Tadesse K, et al. Efficacy and side effects of praziquantel in the treatment of schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia. Asian Pac J Tropical Biomedicine. 2012;2(3):235–239.
   PubMedGoogle Scholar
• Haile S, Golassa L, Mekonnen Z 2012. Prevalence of Schistosoma mansoni and effectiveness of Praziquantel in school children in Finchaa valley, Ethiopia. Journal of Parasitology and Vector Biology 4 (3):25–30. doi:10.5897/JPVB12.013.
   Google Scholar
• Mnkugwe RH, Minzi OS, Kinung’Hi SM, et al. Efficacy and safety of praziquantel for treatment of Schistosoma mansoni infection among school children in Tanzania. Pathogens. 2019;9(1):28.
   PubMed Web of Science ®Google Scholar
• Reta B, Erko B. Efficacy and side effects of praziquantel in the treatment for Schistosoma mansoni infection in school children in Senbete Town, northeastern Ethiopia. Trop Med Int Health. 2013;18(11):1338–1343.
   PubMed Web of Science ®Google Scholar
• Tesfie A, Getnet G, Abere A, et al. Praziquantel is an effective drug for the treatment of Schistosoma mansoni infection among school-aged children in Northwest Ethiopia. Trop Med Health. 2020;48(1):1–8.
   PubMed Web of Science ®Google Scholar
• Woldegerima E, Bayih AG, Tegegne Y, et al. Prevalence and reinfection rates of Schistosoma mansoni and praziquantel efficacy against the parasite among primary school children in Sanja Town, Northwest Ethiopia. J Parasitol Res. 2019;2019:8.
   Google Scholar
• Danso-Appiah A, Olliaro PL, Donegan S, et al. Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev. 2013;(2), CD000528. DOI:10.1002/14651858.CD000528.pub2
   PubMed Web of Science ®Google Scholar
• Danso‐appiah A, Utzinger J, Liu J, et al. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev. 2008;16(3):CD000053.
   Google Scholar
• Botros S, Pica-Mattoccia L, William S, et al. Effect of praziquantel on the immature stages of Schistosoma haematobium. Int J Parasitol. 2005;35(13):1453–1457.
   PubMed Web of Science ®Google Scholar
• Navaratnam AMD, Sousa-Figueiredo JC, Stothard JR, et al. Efficacy of praziquantel syrup versus crushed praziquantel tablets in the treatment of intestinal schistosomiasis in Ugandan preschool children, with observation on compliance and safety. Trans R Soc Trop Med Hyg. 2012;106(7):400–407.
   PubMed Web of Science ®Google Scholar
• Pica-Mattoccia L, Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol. 2004;34(4):527–533.
   PubMed Web of Science ®Google Scholar
• Xiao S, Catto BA, Webster LT. Effects of Praziquantel on Different Developmental Stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis. 1985;151(6):1130–1137.
   PubMed Web of Science ®Google Scholar
• Junquera P. Praziquantel for veterinary use in dogs, cats, horses and livestock as anthelmintic against tapeworms. 2021. [cited 2022 Feb 15]. Available from https://parasitipedia.net/index.php?option=com_content&view=article&id=2500&Itemid=2772
   Google Scholar
• Tchuenté LAT, Momo SC, Stothard JR, et al. Efficacy of praziquantel and reinfection patterns in single and mixed infection foci for intestinal and urogenital schistosomiasis in Cameroon. Acta Trop. 2013;128(2):275–283.
   PubMed Web of Science ®Google Scholar
• Webster BL, Diaw OT, Seye MM, et al. Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns. Acta Trop. 2013;128(2):292–302.
   PubMed Web of Science ®Google Scholar
• Dejon-Agobé JC, Edoa JR, Honkpehedji YJ, et al. Schistosoma haematobium infection morbidity, praziquantel effectiveness and reinfection rate among children and young adults in Gabon. Parasit Vectors. 2019;12(1):1–11.
   PubMed Web of Science ®Google Scholar
• Saathoff E, Olsen A, Magnussen P, et al. Patterns of Schistosoma haematobium infection, impact of praziquantel treatment and re-infection after treatment in a cohort of schoolchildren from rural KwaZulu-Natal/South Africa. BMC Infect Dis. 2004;4(1):1–10.
   PubMedGoogle Scholar
• Tukahebwa EM, Vennervald BJ, Nuwaha F, et al. Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. Trans R Soc Trop Med Hyg. 2013;107(6):397–404.
   PubMed Web of Science ®Google Scholar
• Hammad TA, Gabr NS, Hussein MH, et al. Determinants of infection with schistosomiasis haematobia using logistic regression. Am J Trop Med Hyg. 1997;57(4):464–468.
   PubMed Web of Science ®Google Scholar
• Ndyomugyenyi R, Minjas JN. Urinary schistosomiasis in schoolchildren in Dar-es-Salaam, Tanzania, and the factors influencing its transmission. Ann Trop Med Parasitol. 2001;95(7):697–706.
   PubMed Web of Science ®Google Scholar
• Casavechia MTG, de Melo GDAN, Fernandes ACBDS, et al. Systematic review and meta-analysis on Schistosoma mansoni infection prevalence, and associated risk factors in Brazil. Parasitology. 2018;145(8):1000–1014.
   PubMed Web of Science ®Google Scholar
• Handzel T, Karanja DM, Addiss DG, et al. Geographic distribution of schistosomiasis and soil-transmitted helminths in Western Kenya: implications for anthelminthic mass treatment. Am J Trop Med Hyg. 2003;69(3):318–323.
   PubMed Web of Science ®Google Scholar
• Akogun OB, Akogun MK. Human behaviour, water usage and schistosomiasis transmission in a small settlement near Yola, Nigeria. Ann Trop Med Parasitol. 1996;90(3):303–311.
   PubMed Web of Science ®Google Scholar